A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

作者
Rucha V. Modak,Sara J.C. Gosline,Alisa Damnernsawad,Tamilla Nechiporuk,Ted Laderas,Guanming Wu,Paul Piehowski,Stephen E. Kurtz,Christopher A. Eide,Jeffrey W Tyner,Karin Rodland,Shannon K. McWeeney,Anupriya Agarwal
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 11-12
标识
DOI:10.1182/blood-2020-141686
摘要

Background: The treatment of acute myeloid leukemia (AML) patients is a formidable challenge, due to disease heterogeneity and the ability to acquire secondary mutations in response to treatment. As a result, persistence and expansion of residual AML clones prevents complete remission. Emerging evidence suggests that extrinsic factors from the microenvironment protect AML cells from therapy, promote disease progression and drug resistance. Previous work from our lab highlights that higher levels of proinflammatory cytokines in the microenvironment, promote AML progression. This emphasizes the rationale to implement targeted therapies that block extrinsic signaling along with tumor intrinsic changes to overcome drug resistance in AML. Methods and Results: To identify factors and pathways that promote drug sensitivity and resistance in AML, we quantified the levels of 41 cytokines and growth factors from the plasma of 350 newly diagnosed AML patient samples using a multiplex luminex assay. The same cohort were analyzed for drug response to 122 small molecule inhibitors using an ex vivo functional drug sensitivity assay. These data were integrated with the gene expression and reactome pathway data to identify differentially regulated pathways and markers for drug response. Data integration revealed that protein synthesis pathways were significantly enriched in venetoclax, (Bcl-2 inhibitor) resistant AML samples, whereas, cytokine and immune pathways such as aberrant activation of monocyte chemoattractant protein-1 (MCP-1; p= 4.9e-07) were correlated with resistance to trametinib, a MEK inhibitor. In contrast, trametinib sensitivity was associated with activation of IL-1 and TLR signaling, suggesting specific extrinsic pathways may drive specific drug response. As a proof-of-concept, we dissected the role of MCP-1 activation in mediating trametinib resistance in AML. For this, we treated primary AML cells with MCP-1 in the presence of trametinib that led to a 4-fold increase in IC50 (0.4 vs 2.4 µM). To model drug response in vitro, we generated trametinib resistant AML cell lines MOLM13 and MV4;11 (FLT3-ITD mutated) and OCI-AML2 (DNMT3A mutated) by culturing cells in trametinib continuously over 4 months. All the trametinib resistant AML cell lines showed 2-10-fold increase in MCP-1 levels in whole cell lysate and in the conditioned media compared to the parental cells. Further, a long-term exposure of AML cells to MCP-1 in the presence of trametinib conferred a growth advantage with a 4-fold increase in cell numbers in comparison to the cells cultured with trametinib alone (n=4/condition). To delineate the molecular pathways driven by MCP-1 in trametinib resistance, we performed global phosphoproteomics using AML cell lines. We identified that MCP-1 activated various pro-survival pathways such as ERK, JNK, SRC, P70, and PKC kinases as well as cell cycle regulatory proteins as early as 5 mins in trametinib resistant cells. Targeting MCP-1 receptor-CCR2 by pharmacological inhibition, significantly reduced viability of trametinib resistant AML cells by 3-fold. The treatment with CCR2 inhibitor or trametinib individually reduced p-JNK levels by 3-fold in AML cells. A combined treatment with CCR2 inhibitor and trametinib, showed a 7-fold reduction in p-JNK levels. These data reinforced the role of MCP-1 in conferring trametinib resistance and that blockade of MCP-1 signaling re-sensitizes AML cells to trametinib. Conclusion: We show that MCP-1 augments trametinib resistance in AML by triggering novel signaling pathways. These effects can be reversed by blockade of MCP-1-CCR2 axis. Such combination treatment strategy incorporating extrinsic pathways together with the intrinsic ones would aid in re-sensitizing AML cells to therapy and represent an attractive new strategy. Our functional screen identifies that these extrinsic signals modulating drug response are unique to specific targeted therapy and should be considered when designing new therapies and clinical trials. We also created a large resource with 350 primary AML samples correlating microenvironment factors and gene expression with response to 122 small molecules, many of those which are FDA approved. This resource will help identify new drug response pathways in the context of microenvironment to design novel treatment regimens for preclinical and clinical testing and to improve AML outcomes. Disclosures Tyner: Syros: Research Funding; Agios: Research Funding; Incyte: Research Funding; Seattle Genetics: Research Funding; Takeda: Research Funding; Petra: Research Funding; Janssen: Research Funding; Constellation: Research Funding; Aptose: Research Funding; Genentech: Research Funding; Gilead: Research Funding; Array: Research Funding; AstraZeneca: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
王炜德完成签到,获得积分10
3秒前
大知闲闲发布了新的文献求助10
3秒前
ye发布了新的文献求助10
4秒前
风吹麦浪发布了新的文献求助10
4秒前
gsz发布了新的文献求助10
4秒前
许迪完成签到,获得积分10
4秒前
4秒前
5秒前
四字完成签到,获得积分10
5秒前
NiuNiu4完成签到,获得积分10
5秒前
6秒前
6秒前
ranrika完成签到,获得积分10
6秒前
无花果的应助被ddd采纳,获得10
7秒前
7秒前
王悦完成签到,获得积分10
7秒前
8秒前
8秒前
8秒前
余谏己完成签到 ,获得积分10
9秒前
深情安青的应助被科研通管家采纳,获得10
9秒前
天天向上的应助被科研通管家采纳,获得30
9秒前
9秒前
Jasper的应助被科研通管家采纳,获得30
9秒前
上官若男的应助被科研通管家采纳,获得10
9秒前
赘婿的应助被科研通管家采纳,获得10
9秒前
Akim的应助被pinguin采纳,获得10
9秒前
JamesPei的应助被科研通管家采纳,获得10
9秒前
DW的应助被科研通管家采纳,获得10
9秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
10秒前
leecopper001发布了新的文献求助10
10秒前
搜集达人的应助被科研通管家采纳,获得10
10秒前
小二郎的应助被科研通管家采纳,获得10
10秒前
ding的应助被科研通管家采纳,获得10
10秒前
why发布了新的文献求助10
10秒前
orixero的应助被科研通管家采纳,获得10
10秒前
上官若男的应助被科研通管家采纳,获得10
10秒前
10秒前
华仔的应助被科研通管家采纳,获得30
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611